Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

10 Dec 2020

Nasal Drug Delivery: Past, Present and Future Perspectives

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
30 Nov 2020

Exploring the role of EI in partnerships for OINDP development

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
5 Nov 2020

The Need to Scale Up Digital Health in the Post-Covid World

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
6 Oct 2020

Using Bioequivalence and Particle Size Distribution to Develop OINDPs

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 … 18 19 20 21 22 … 25

How Can We Help?

Back To Top